Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
161
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
stocks
Major ASX listed miners overvalued
stocks
Undervalued ASX share with pathway to positive cash flow
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,194.90 | 12.40 | -0.13% |
| CAC 40 | 8,092.05 | 166.89 | -2.02% |
| DAX 40 | 24,935.11 | 362.02 | -1.43% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,198.17 | 37.12 | -0.36% |
| HKSE | 26,563.90 | 281.06 | -1.05% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,583.57 | 352.60 | -0.65% |
| NZX 50 Index | 13,580.29 | 137.81 | -1.00% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,874.50 | 9.20 | -0.10% |
| SSE Composite Index | 4,114.00 | 12.09 | 0.29% |